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Abstract
Introduction: The prolonged QTc interval predisposes to serious arrhythmias. Various medications, 
including antiretrovirals, can prolong it. The objectives were to determine the demographic, clinical 
characteristics and the frequency of the prolonged QTc interval in patients with HIV. Methods: We 
conducted a prospective, observational study with a control group. Men and women, over 18 years of 
age, with HIV infection, who attended the National Hospital (Itauguá, Paraguay) during 2020, were 
included. Medical students acted as a control group. All subjects who did not give their consent and 
those with arrhythmias were excluded. Demographic, clinical, laboratory variables and 12-channel 
electrocardiogram at rest were measured. The study was approved by the Ethics Committee of the 
Private University of the East (Paraguay). Results: A total of 39 HIV patients and 39 healthy controls 
was entered to the research. The mean age of the cases was 37 ± 11 years, being 59% male. The 
most frequent comorbidity in the cases was obesity (7.6%). The mean values  of urea, creatinine, K, 
Ca and Mg in the cases were in the normal range. Prolonged QTc was detected in 18% of the cases 
and in 0% of the controls. The subjects with the electrocardiographic alteration were all on 
antiretroviral and multiple antibiotic treatment known to be associated with prolonged QTc. 
Conclusion: the frequency of prolonged QTc in HIV patients was 18% and in healthy controls it was 
0%. Regular monitoring of the electrocardiogram is recommended in HIV patients receiving drugs 
that prolong the QT interval.
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Resumen
Introducción: el intervalo QTc prolongado predispone a arritmias graves. Diversos medicamentos, 
entre ellos los antirretrovirales, pueden prolongarlo.  Los objetivos fueron determinar las 
características demográficas, clínicas y la frecuencia del intervalo QTc prolongado en pacientes con 
VIH. Métodos: estudio observacional, prospectivo, con grupo control. Se incluyeron varones y 
mujeres, mayores de 18 años, portadores de infección por VIH, que acudieron al Hospital Nacional 
(Itauguá, Paraguay) durante 2020. Actuaron como grupo control los estudiantes de Medicina. Se 
excluyeron todos los sujetos que no dieron su consentimiento y los portadores de arritmias. Se 
midieron variables demográficas, clínicas, laboratoriales y electrocardiograma de 12 canales en 
reposo. El estudio contó con la aprobación del Comité de Ética de la Universidad Privada del Este 
(Paraguay). Resultados: ingresaron al estudio 39 pacientes con VIH y 39 controles sanos. La edad 
media de los casos fue 37 ± 11 años, siendo 59% del sexo masculino. La comorbilidad más frecuente 
en los casos fue la obesidad (7,6%). Los valores medios de urea, creatinina, K, Ca y Mg en los casos 
se hallaban en rango normal. Se detectó 18% de QTc prolongado en casos y 0% en los controles. 
Estos sujetos con alteración electrocardiográfica se hallaban todos en tratamiento antirretroviral y 
antibiótico múltiple de conocida asociación con QTc prolongado. Conclusión: la frecuencia de QTc 
prolongado en pacientes con VIH fue del 18% y en controles sanos fue del 0%. Se recomienda el 
control periódico del electrocardiograma en pacientes con VIH en tratamiento con fármacos que 
prolongan el intervalo QT.
Palabras clave: síndrome de QT prolongado, electrocardiografía, VIH, antirretrovirales.
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Introduction
Ventricular depolarization and repolarization are 
represented on the electrocardiogram (ECG) by the 
QT interval (1). The duration of the QT interval can 
have circadian, age and gender variations. But the 
most influential factor is the heart rate, hence this 
interval must be corrected: it is the corrected QT 
interval (QTc) (2). The QTc should not be greater 
than 0.45 sec in men and 0.47 sec in women, 
otherwise it is called long or prolonged QT 
syndrome (LQTS) (3). Other authors consider 
SQTP when at least 2 ECGs with QTc> 0.50 sec are 
detected (4,5). Any new QTc prolongation> 0.30 sec 
with respect to the baseline ECG should attract 
attention and when it is> 0.60 sec, therapeutic 
measures should be taken (6). The risk of adverse 
cardiac events increases exponentially with QTc 
prolongation: for every 0.10 sec increase in QTc 
there is a 5% increase in the risk of arrhythmic 
events. Measurement of QT dispersion is cumber-
some and does not provide additional data on the 
risk of arrhythmias. However, a change in the 
morphology of the T wave and the variation of the 
Tpeak / Tbase index are better predictors of 
arrhythmias (7).
PCOS is a disease characterized by prolonged 
ventricular repolarization time and predisposition to 
life-threatening ventricular arrhythmias. Long QT is 
related to the appearance of early postpotentials 
and increased dispersion of the QT period in the 
different layers of the cardiac myocardium (8). The 
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women (1,3).
For convenience, all subjects who met the inclusion 
criteria in the planned study period were 
incorporated. Descriptive statistics were performed 
with the Epi Info 7 © program. The qualitative 
variables were expressed in frequencies and 
percentages, while the quantitative variables in 
measures of central tendency and dispersion.
Ethical aspects: the confidentiality of personal data 
was respected. Patients or dependents could 
voluntarily decide to participate in the research. No 
type of discrimination was made when selecting the 
subjects. This research did not involve harm to the 
patients or cost them. The patients were informed in 
their native language of the procedures to be carried 
out and signed an informed consent. When each 
case of PCOS was detected, the treating physician 
was immediately informed so that he could take the 
pertinent measures. The authors declare that they 
have no conflicts of commercial interest. The 
protocol was evaluated and approved by the 
Research Committee and the Ethics Committee of 
the Private University of the East (Paraguay).
Results
Between March and December 2020, 39 patients 
with HIV and 47 healthy controls were included 
(graphic 1).
The subjects with HIV (n 39) were male (61.5%) and 
female (38.5%), with a mean age 37 ± 11 years. 
Controls (n 47) were male (36%) and female (64%), 
with a mean age of 26 ± 2 years. The mean BMI of 
the patients with HIV was 22.5 ± 4.0 k / m2. The 
nutritional states were: malnutrition 3 (7.7%), 
normal 25 (64.1%), overweight 8 (20.5%) and 
obesity 3 (7.7%). In 31 (79.4%) subjects no 
comorbidity was detected, those found were obesity 
3 (7.6%), valvular heart disease 1 82.6%), 
alcoholism 1 (2.6%), systemic lupus erythematosus 
1 (2.6%), arterial hypertension 1 (2.6%), arterial 
hypertension and diabetes mellitus 1 (2.6%). The 
laboratory parameters of patients with HIV are 
described in Table 1.
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cause of PCOS can be congenital or acquired. The 
congenital form is genetic in origin and is quite rare. 
But acquired is much more frequent and is 
secondary to the action of drugs, fluid and 
electrolyte disorders (hypokalaemia, hypomag-
nesemia, and hypocalcemia), ischemic heart 
disease, cardiomyopathies, extreme bradycardia, 
subarachnoid hemorrhage, hypothyroidism, 
acidosis, and AIDS. Therefore, many acquired 
forms of PTS are preventable (9).
The drugs involved are diverse: antiarrhythmics, 
ant ib iot ics,  ant iv i ra ls ,  azole ant i fungals, 
antimalarials, antineoplastics, antiemetics, 
prokinetics, antipsychotics, antidepressants, 
among others (8). The combination of macrolides 
and quinolones is common but is not recommended 
due to its effects on QTc prolongation (6). The 
Arizona Center for Education and Research on 
Therapeutics (AZCERT) initiative to register drugs 
related to QTc prolongation has led to updated lists 
of drugs with this effect. These lists are freely 
available on the internet and are widely used in 
research and clinical practice. The drugs are 
classified into 4 groups: prohibited in SQTP, known 
effect on QTc, probable effect on QTc and effect on 
QTc conditioned by other factors (10).
Although many drugs prolong the QT interval, tip 
torsion is a rare event: 4 per 100,000 patients. But 
this frequency increases when risk factors are 
added. The following conditions increase this risk: 
heart failure, structural heart disease, bradycardia, 
hypokalaemia, hypomagnesaemia, hypocal-
caemia, subclinical ion channel mutations, high 
doses of drugs, old age, metabolism inhibitors, 
combination of two or more drugs that prolong blood 
pressure. QT interval (2). The female sex, due to the 
effect of estrogens, generates more susceptibility to 
QTc prolongation. Caucasians are more likely than 
others to suffer from PCOS. HIV infection, 
especially in the AIDS stage, is another predis-
posing factor for PCOS due to various factors 
including the side effects of antiretrovirals (11).
This research was justified because according to 
data from PRONASIDA, HIV infection in Paraguay 
shows a progressive annual increase reaching the 
epidemic range (12). Current treatment for HIV 
infection in Paraguay includes 3 drugs: efavirenz 
600 mg / emtricitabine 200 mg / tenofovir disoproxil 
245 mg. The frequency of ECG alterations in AIDS 
patients is between two and three times that of the 
general population, which increases cardiovascular 
risk in these patients (13-15). Although the SQTP in 
patients with HIV is multifactorial, the ECG is 
capable of detecting potentially fatal abnormalities 
(5,16,17). This is a rapid, non-invasive diagnostic 
method with a high predictive value for cardio-
vascular complications (13,14). Continuous 
measurement of the QTc interval is recommended 
in patients receiving antiretrovirals (18). A similar 
study in patients from Medical Clinic PCOS in some 
patients with HIV (19), which is why this 
investigation focused on these subjects.
The objectives were to determine the frequency of 
PCOS in HIV-positive adult patients of the Medical 
Clinic Service of the National Hospital (Itauguá, 
Paraguay) in 2020, to describe the demographic 
(age, sex), clinical (BMI, clinical stage of infection by 
HIV, type and duration of antiretroviral treatment, 
other medications, comorbidities) and laboratory 
tests (serum urea, creatinine, potassium, calcium 
and magnesium). In addition, detail the drugs 
administered according to the AZCERT list: known 
association, possible association, conditional 
association. Healthy subjects were used to use the 
frequency of QTc interval alterations in them as a 
population parameter in the country.
Methods
An observational, descriptive, prospective, cross-
sectional design was applied, with a control group. 
The study population consisted of men and women, 
over 18 years of age, HIV carriers who attended the 
Medical Clinic Service of the National Hospital 
(Itauguá, Paraguay) between March and November 
2020. As a control group, ECGs were performed at 
different Medicine students. This sample served as 
a frequency parameter for congenital SQTP in the 
country.
The inclusion criterion was current 12-channel ECG 
without technique artifacts. Patients with atrial 
fibrillation, electrical conduction disorders, 
preexcitation syndrome, pacemaker rhythm, 
complete right or left bundle branch blocks, left 
ventricular hypertrophy by voltage criterion were 
excluded. All these criteria made it possible to 
exclude those patients with PTSD induced by non-
drug factors.
A non-probabilistic sampling of consecutive cases 
was used. Demographic variables (age, sex), 
clinical variables (BMI, clinical stage of HIV 
infection, type and duration of antiretroviral 
treatment, other medications, comorbidities) were 
determined. In addition, laboratory data (serum 
urea, creatinine, K, Ca and Mg).
The QT interval and the RR interval were measured 
in lead D1, aVL, V5 and V6 using the average of the 
values  obtained in at least 3 cardiac cycles. In the 
case of sinus arrhythmia, the average of three 
measurements in the same lead was used. The end 
of the T wave was determined by the point at which it 
meets the isoelectric baseline or by the intersection 
of an extrapolated line on the isoelectric line and the 
tangent line that touches the end of the T wave at 
the most extreme point. lower. To obtain the 
corrected QT, Bazett's formula was applied, in 
which the QT interval measured in seconds is 
divided by the square root of the preceding RR time 
expressed in seconds. Prolonged QTc was 
considered if ≥0.45 sec in men and ≥0.47 sec in 
Graphic 1. Flowchart of sample inclusion
Table 1. Laboratory parameters of patients with HIV (n 39)
Laboratory parameters Mean ± DE Range
Hemoglobin (g/dL) 10,6 ± 7,2 4,5 - 15,2
Urea (mg/dL) 29,3 ± 20,9 8 - 120 
Creatinine (mg/dL) 0,7 ± 0,3 0,08 - 1,7
Potassium (mEq/L) 4,1 ± 0,7 2,7 - 7,2
Magnesium (mg/dL) 2 ± 0,2 1,6 - 2,7
Calcium (mg/dL) 8,5 ± 0,8 7 - 10,3
All HIV carriers were in stage C (AIDS), who were 
admitted to the hospital room for opportunistic 
diseases. The median viral load was 38,466 (range 
80 - 11,000,000 and the median CD4 count was 80 
(range 22 - 644). In 11 (28%) subjects, recruitment 
was carried out when debuting with AIDS, while 28 ( 
72%) were on Atripla © treatment for an average of 
12 months.
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women (1,3).
For convenience, all subjects who met the inclusion 
criteria in the planned study period were 
incorporated. Descriptive statistics were performed 
with the Epi Info 7 © program. The qualitative 
variables were expressed in frequencies and 
percentages, while the quantitative variables in 
measures of central tendency and dispersion.
Ethical aspects: the confidentiality of personal data 
was respected. Patients or dependents could 
voluntarily decide to participate in the research. No 
type of discrimination was made when selecting the 
subjects. This research did not involve harm to the 
patients or cost them. The patients were informed in 
their native language of the procedures to be carried 
out and signed an informed consent. When each 
case of PCOS was detected, the treating physician 
was immediately informed so that he could take the 
pertinent measures. The authors declare that they 
have no conflicts of commercial interest. The 
protocol was evaluated and approved by the 
Research Committee and the Ethics Committee of 
the Private University of the East (Paraguay).
Results
Between March and December 2020, 39 patients 
with HIV and 47 healthy controls were included 
(graphic 1).
The subjects with HIV (n 39) were male (61.5%) and 
female (38.5%), with a mean age 37 ± 11 years. 
Controls (n 47) were male (36%) and female (64%), 
with a mean age of 26 ± 2 years. The mean BMI of 
the patients with HIV was 22.5 ± 4.0 k / m2. The 
nutritional states were: malnutrition 3 (7.7%), 
normal 25 (64.1%), overweight 8 (20.5%) and 
obesity 3 (7.7%). In 31 (79.4%) subjects no 
comorbidity was detected, those found were obesity 
3 (7.6%), valvular heart disease 1 82.6%), 
alcoholism 1 (2.6%), systemic lupus erythematosus 
1 (2.6%), arterial hypertension 1 (2.6%), arterial 
hypertension and diabetes mellitus 1 (2.6%). The 
laboratory parameters of patients with HIV are 
described in Table 1.
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cause of PCOS can be congenital or acquired. The 
congenital form is genetic in origin and is quite rare. 
But acquired is much more frequent and is 
secondary to the action of drugs, fluid and 
electrolyte disorders (hypokalaemia, hypomag-
nesemia, and hypocalcemia), ischemic heart 
disease, cardiomyopathies, extreme bradycardia, 
subarachnoid hemorrhage, hypothyroidism, 
acidosis, and AIDS. Therefore, many acquired 
forms of PTS are preventable (9).
The drugs involved are diverse: antiarrhythmics, 
ant ib iot ics,  ant iv i ra ls ,  azole ant i fungals, 
antimalarials, antineoplastics, antiemetics, 
prokinetics, antipsychotics, antidepressants, 
among others (8). The combination of macrolides 
and quinolones is common but is not recommended 
due to its effects on QTc prolongation (6). The 
Arizona Center for Education and Research on 
Therapeutics (AZCERT) initiative to register drugs 
related to QTc prolongation has led to updated lists 
of drugs with this effect. These lists are freely 
available on the internet and are widely used in 
research and clinical practice. The drugs are 
classified into 4 groups: prohibited in SQTP, known 
effect on QTc, probable effect on QTc and effect on 
QTc conditioned by other factors (10).
Although many drugs prolong the QT interval, tip 
torsion is a rare event: 4 per 100,000 patients. But 
this frequency increases when risk factors are 
added. The following conditions increase this risk: 
heart failure, structural heart disease, bradycardia, 
hypokalaemia, hypomagnesaemia, hypocal-
caemia, subclinical ion channel mutations, high 
doses of drugs, old age, metabolism inhibitors, 
combination of two or more drugs that prolong blood 
pressure. QT interval (2). The female sex, due to the 
effect of estrogens, generates more susceptibility to 
QTc prolongation. Caucasians are more likely than 
others to suffer from PCOS. HIV infection, 
especially in the AIDS stage, is another predis-
posing factor for PCOS due to various factors 
including the side effects of antiretrovirals (11).
This research was justified because according to 
data from PRONASIDA, HIV infection in Paraguay 
shows a progressive annual increase reaching the 
epidemic range (12). Current treatment for HIV 
infection in Paraguay includes 3 drugs: efavirenz 
600 mg / emtricitabine 200 mg / tenofovir disoproxil 
245 mg. The frequency of ECG alterations in AIDS 
patients is between two and three times that of the 
general population, which increases cardiovascular 
risk in these patients (13-15). Although the SQTP in 
patients with HIV is multifactorial, the ECG is 
capable of detecting potentially fatal abnormalities 
(5,16,17). This is a rapid, non-invasive diagnostic 
method with a high predictive value for cardio-
vascular complications (13,14). Continuous 
measurement of the QTc interval is recommended 
in patients receiving antiretrovirals (18). A similar 
study in patients from Medical Clinic PCOS in some 
patients with HIV (19), which is why this 
investigation focused on these subjects.
The objectives were to determine the frequency of 
PCOS in HIV-positive adult patients of the Medical 
Clinic Service of the National Hospital (Itauguá, 
Paraguay) in 2020, to describe the demographic 
(age, sex), clinical (BMI, clinical stage of infection by 
HIV, type and duration of antiretroviral treatment, 
other medications, comorbidities) and laboratory 
tests (serum urea, creatinine, potassium, calcium 
and magnesium). In addition, detail the drugs 
administered according to the AZCERT list: known 
association, possible association, conditional 
association. Healthy subjects were used to use the 
frequency of QTc interval alterations in them as a 
population parameter in the country.
Methods
An observational, descriptive, prospective, cross-
sectional design was applied, with a control group. 
The study population consisted of men and women, 
over 18 years of age, HIV carriers who attended the 
Medical Clinic Service of the National Hospital 
(Itauguá, Paraguay) between March and November 
2020. As a control group, ECGs were performed at 
different Medicine students. This sample served as 
a frequency parameter for congenital SQTP in the 
country.
The inclusion criterion was current 12-channel ECG 
without technique artifacts. Patients with atrial 
fibrillation, electrical conduction disorders, 
preexcitation syndrome, pacemaker rhythm, 
complete right or left bundle branch blocks, left 
ventricular hypertrophy by voltage criterion were 
excluded. All these criteria made it possible to 
exclude those patients with PTSD induced by non-
drug factors.
A non-probabilistic sampling of consecutive cases 
was used. Demographic variables (age, sex), 
clinical variables (BMI, clinical stage of HIV 
infection, type and duration of antiretroviral 
treatment, other medications, comorbidities) were 
determined. In addition, laboratory data (serum 
urea, creatinine, K, Ca and Mg).
The QT interval and the RR interval were measured 
in lead D1, aVL, V5 and V6 using the average of the 
values  obtained in at least 3 cardiac cycles. In the 
case of sinus arrhythmia, the average of three 
measurements in the same lead was used. The end 
of the T wave was determined by the point at which it 
meets the isoelectric baseline or by the intersection 
of an extrapolated line on the isoelectric line and the 
tangent line that touches the end of the T wave at 
the most extreme point. lower. To obtain the 
corrected QT, Bazett's formula was applied, in 
which the QT interval measured in seconds is 
divided by the square root of the preceding RR time 
expressed in seconds. Prolonged QTc was 
considered if ≥0.45 sec in men and ≥0.47 sec in 
Graphic 1. Flowchart of sample inclusion
Table 1. Laboratory parameters of patients with HIV (n 39)
Laboratory parameters Mean ± DE Range
Hemoglobin (g/dL) 10,6 ± 7,2 4,5 - 15,2
Urea (mg/dL) 29,3 ± 20,9 8 - 120 
Creatinine (mg/dL) 0,7 ± 0,3 0,08 - 1,7
Potassium (mEq/L) 4,1 ± 0,7 2,7 - 7,2
Magnesium (mg/dL) 2 ± 0,2 1,6 - 2,7
Calcium (mg/dL) 8,5 ± 0,8 7 - 10,3
All HIV carriers were in stage C (AIDS), who were 
admitted to the hospital room for opportunistic 
diseases. The median viral load was 38,466 (range 
80 - 11,000,000 and the median CD4 count was 80 
(range 22 - 644). In 11 (28%) subjects, recruitment 
was carried out when debuting with AIDS, while 28 ( 
72%) were on Atripla © treatment for an average of 
12 months.
177
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(3), july - september: 173-179
Frequency of QTc interval prolongation in HIV-infected adults from Paraguay in 2020176
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(3), july - september: 173-179
Table 3. Clinical and laboratory characteristics of patients with HIV in relation to the QTc interval (n 39)
Table 4.  Frequency of drugs ingested by patients with prolonged QTc classified according to the risk of 
developing arrhythmias (n 7)
Table 2. Electrocardiographic findings with HIV patients and healthy controls
Figure 1. Electrocardiographic tracing of a 28-year-old woman treated with antiretrovirals 2 years ago, 
omeprazole and carbamazepine. QTc of 0.55 msec is observed.
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All patients were in sinus rhythm. The electrocar- diographic findings are detailed in Table 2.
Patients with
VIH (n 39)
Rate (beats / min) 89 ± 22 78 ± 13
PR interval (msec) 0,14 ± 0,02 0,14 ± 0,02
QT interval (msec) 0,33 ± 0,05 0,33 ± 0,02





Applying a cut-off point of ≥0.45 sec in men and 
≥0.47 sec in women, 7 subjects (18%) were found in 
the cases with HIV and in none of the healthy 
controls (graphic 1 and figure 1).
The 7 cases with prolonged QTc were characterized 
by all being on antiretroviral treatment. There was 
no significant variation in the other clinical and 
laboratory parameters (Table 3).
With QTc With QTc
prolonged (n 7) normal (n 32)
Sex female/male 3/4 12/20
Edad (mean ± SD) 39 ± 10 37 ± 11
BMI (mean ± SD) 21 ± 5 23 ± 4
Urea (mean ± SD) 37 ± 29 27 ± 19
Creatinine (mean ± SD) 0,9 ± 0,4 0,7 ± 0,1
Potassium (mean ± SD) 3,6 ± 0,6 4,2 ± 0,7
Magnesium (mean ± SD) 2 ± 0,3 2 ± 0,2
Calcium (mean ± SD) 8,8 ± 0,6 8,5 ± 0,8
With antiretrovirals (n 28) 7 (100%) 21 (65%)
Clinical
characteristics
All patients with HIV were polypharmacy. The 
medications most used by the 7 patients with 
prolonged QTc and their relationship with the risk of 
developing arrhythmias according to AZCERT are 
described in Table 4.
Discussion
National SQTP data in Medical Clinic patients report 
a frequency of 21% but included few AIDS patients 
azithromycin (71%) efavirenz (100%) omeprazol (100%) cotrimoxazole (57%)










(19). In this study, the frequency of PCOS was very 
high (18%), even more so when compared with 
healthy controls, which shows the clear association 
between HIV, antiretroviral drugs and QT interval 
alteration.
According to various authors, the frequency of 
PCOS in HIV-infected patients varies between 1.1 
and 45% (13,14,20,21). In studies where control 
groups were used, the frequency of PTSD was 
higher in patients with HIV: 34% vs. 10.5% (22), 
22.8% vs. 3.9% (15), 11% vs. 9%, 29% vs. 7%, 32% 
vs. 4.7%, 48% vs. 8%. This demonstrates the clear 
association between this disorder on the ECG and 
HIV infection, although the etiology of this 
abnormality is multifactorial (23).
The QTc interval is an electrical activity mediated by 
channels that regulate ionic fluxes through it. The 
rapid entry of positive Na and Ca ions through these 
channels is responsible for normal myocardial 
depolarization, while repolarization occurs when 
this flow is exceeded by the exit of K ions (24). The 
dysfunction of these channels or channelopathy 
generates an intracellular excess of cations (Na and 
K), either due to insufficient K output or excessive 
Na input, which delays ventricular repolarization 
and the QT interval is prolonged (2). In this sample, 
no abnormalities in electrolyte concentrations were 
detected to explain the SQTP.
Increased duration of the QT interval on the ECG 
has been associated with an increased risk of 
severe arrhythmias and sudden death, as it favors 
the development of the potentially fatal "tip torsion" 
helical ventricular tachycardia. Arrhythmias can 
manifest as palpitations, syncope, cardiogenic 
shock, or sudden death (7). Sudden death is 
understood to be that which occurs within 1 h in a 
person with no previous signs of fatality. The 
autopsy does not show organic signs of myocardial 
damage, since one cause could be arrhythmogenic 
channelopathies, especially in those under 40 years 
of age (4). Fortunately, no in-hospital death 
occurred in this sample.
Alterations in the ECG of AIDS patients can occur in 
all waves and segments (25) (26). Soliman et al. 
found these alterations in 51% while in the general 
population it was only in 16 to 32% (13). These ECG 
abnormalities were associated with greater 
cardiovascular complications, especially in subjects 
with comorbidities such as dyslipidemia, arterial 
hypertension, diabetes mellitus, and smoking. 
Autonomic neuropathy increases the frequency of 
PCOS to 65% (21) (26). In this study, the patients 
with HIV did not present mainly comorbidities, so 
the PQTS cannot be attributed to them.
In this sample, all the subjects with PCOS were on 
antiretroviral treatment and also received 
medications registered on the AZCERT list, due to 
their known association with this electrocardio-
graphic alteration (10). Unfortunately, there are no 
ECG records at the start of treatment or follow-up at 
discharge.
Antiretroviral treatment in Paraguay includes 
efavirenz / emtricitabine / tenofovir disoproxil. The 
former is a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) while the others are nucleoside 
reverse transcriptase inhibitor (NNRTI) (16). Except 
for efavirenz, this formulation has mostly renal 
excretion (27). Many antiretrovirals are associated 
with SQTP. The concomitant use of macrolides, 
cotrimoxazole, antivirals and antifungals, very 
common in AIDS, increases the risk of QTc interval 
prolongation (14,15). The risk of sudden death in 
patients with HIV is 4.5 times more frequent than in 
subjects without this infection (5). This risk is due 
not only to PCOS but also to the increase in 
coronary risk factors due to chronic inflammation, 
dyslipidemia, endothelial and platelet dysfunction, 
generating ischemic heart disease and heart failure 
(27).
A weakness of this research is the small sample 
size. This was due to the fact that outpatients could 
not be recruited due to the contact restriction 
established by the health protocol as a result of the 
SARS-CoV-2 pandemic (28). For this reason, only 
the internees were included. Another weakness is 
the cross-sectional design that prevents determi-
ning the association between variables and 
evolutionary monitoring. Nor can it be conclusively 
concluded that only antiretrovirals were the cause of 
PTSD due to polypharmacy, which is difficult to 
avoid in these complex patients. But as a strength, it 
should be mentioned that it is the first study to 
address this issue in patients with HIV in this referral 
hospital, an aspect that must be taken into account 
in their follow-up. For this reason, ECG is recom-
mended when starting and during antiretroviral 
treatment (29,30).
In conclusion, the frequency of SQTP in HIV 
patients was 18% and 0% in healthy controls. All 
these patients with electrocardiographic alteration 
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Table 3. Clinical and laboratory characteristics of patients with HIV in relation to the QTc interval (n 39)
Table 4.  Frequency of drugs ingested by patients with prolonged QTc classified according to the risk of 
developing arrhythmias (n 7)
Table 2. Electrocardiographic findings with HIV patients and healthy controls
Figure 1. Electrocardiographic tracing of a 28-year-old woman treated with antiretrovirals 2 years ago, 
omeprazole and carbamazepine. QTc of 0.55 msec is observed.
Real-Delor RE, Brítez-Calderón SJE, Carballo-Báez VV, Cuevas-Machuca DN, Díaz-Fretes SA, Escurra-Torres MA, Escurra-Torres RD, García-Almirón DM, González-Cantero EM, Halke-Saiz JR, 
Larrea-Alarcón AL, Medina-Valdez PN, Mendoza-Ayala KN, Orrego-Martínez AE, Ortiz-Martínez JL, Pirelli-Cubas GJ, Tobal-Gómez ME
All patients were in sinus rhythm. The electrocar- diographic findings are detailed in Table 2.
Patients with
VIH (n 39)
Rate (beats / min) 89 ± 22 78 ± 13
PR interval (msec) 0,14 ± 0,02 0,14 ± 0,02
QT interval (msec) 0,33 ± 0,05 0,33 ± 0,02
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Magnesium (mean ± SD) 2 ± 0,3 2 ± 0,2
Calcium (mean ± SD) 8,8 ± 0,6 8,5 ± 0,8
With antiretrovirals (n 28) 7 (100%) 21 (65%)
Clinical
characteristics
All patients with HIV were polypharmacy. The 
medications most used by the 7 patients with 
prolonged QTc and their relationship with the risk of 
developing arrhythmias according to AZCERT are 
described in Table 4.
Discussion
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a frequency of 21% but included few AIDS patients 
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were on antiretroviral treatment and received drugs 
recognized for generating this electrocardiographic 
abnormal i ty.  Per iodic ECG monitor ing is 
recommended in HIV patients receiving drugs that 
prolong the QT interval, as well as methodological 
designs that assess risk.
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